Article ; Online: Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
2021 Volume 100, Issue 9, Page(s) 2325–2337
Abstract: ... comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D ...
| Abstract | Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was followed between 1/2007 and 3/2018 in Optum's deidentified US electronic health records database. Time to next treatment (TTNT) was estimated using Kaplan-Meier methods; regimens were compared using covariate-adjusted Cox proportional hazard models. Seven hundred forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349; KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd, n = 45) in LOTs ≥2 were identified. More patients ≥75 years received IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted median TTNT in LOT ≥ 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In covariate-adjusted analysis, only KRd vs DRd was associated with a significantly higher risk of next LOT initiation/death (HR 1.72; P = 0.0142); no Pd triplet was significantly different vs DPd in LOT ≥ 2. Our data highlight important efficacy/effectiveness gaps between results observed in phase 3 clinical trials and those realized in the RW. |
|---|---|
| MeSH term(s) | Aged ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Boron Compounds/therapeutic use ; Bortezomib/therapeutic use ; Female ; Glycine/analogs & derivatives ; Glycine/therapeutic use ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Oligopeptides/therapeutic use ; Retrospective Studies ; Treatment Outcome |
| Chemical Substances | Antibodies, Monoclonal ; Boron Compounds ; Oligopeptides ; daratumumab (4Z63YK6E0E) ; Bortezomib (69G8BD63PP) ; ixazomib (71050168A2) ; carfilzomib (72X6E3J5AR) ; Glycine (TE7660XO1C) |
| Language | English |
| Publishing date | 2021-05-10 |
| Publishing country | Germany |
| Document type | Comparative Study ; Journal Article |
| ZDB-ID | 1064950-5 |
| ISSN | 1432-0584 ; 0939-5555 ; 0945-8077 |
| ISSN (online) | 1432-0584 |
| ISSN | 0939-5555 ; 0945-8077 |
| DOI | 10.1007/s00277-021-04534-8 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.181: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.